Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TOP2A | P11388 | 6/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.32 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12942597 | 0.91 | TOP2A (0.41) | TOP2A | |
| SCHEMBL5188453 | 0.91 | TOP2A (0.41) | TOP2A | |
| SCHEMBL5188458 | 0.91 | TOP2A (0.41) | TOP2A | |
| SCHEMBL25401061 | 0.91 | LMNA (0.32) | LMNASMN1; SMN2TOP2AESR1MAPT | |
| SCHEMBL26285394 | 0.89 | LMNA (0.38) | LMNASMN1; SMN2TOP2AESR1MAPT | |
| SCHEMBL25398507 | 0.89 | LMNA (0.38) | LMNASMN1; SMN2TOP2AESR1MAPT | |
| SCHEMBL25399495 | 0.86 | LMNA (0.37) | LMNASMN1; SMN2TOP2AESR1MAPT | |
| SCHEMBL25403266 | 0.85 | LMNA (0.33) | LMNASMN1; SMN2TOP2AESR1MAPT | |
| SCHEMBL25399189 | 0.82 | TYMS (0.34) | LMNASMN1; SMN2TOP2AESR1MAPT | |
| SCHEMBL25400632 | 0.82 | LMNA (0.38) | LMNASMN1; SMN2TOP2AESR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4493573-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | Rome Therapeutics, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12187758-B2 | Compounds and methods for treating disease | ROME THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023178133-A9 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023178133-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | LMNA 2032/4885SMN1; SMN2 152/4885TOP2A 228/4885 |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | LMNA 2032/4885SMN1; SMN2 152/4885TOP2A 228/4885 |
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | LMNA 2032/4885SMN1; SMN2 152/4885TOP2A 228/4885 |
| US-12187758-B2 | Compounds and methods for treating disease | EHMT1, POLRMT, RNASE1 | LMNA 2032/4885SMN1; SMN2 152/4885TOP2A 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.